Pancreatic Cancer Research

ResearcherArizona State UniversityActive in the last 2 years

Erkut Hasan Borazanci

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5136-5462; OpenAlex author ID A5070523850. Sources: OpenAlex.

Their work

Papers
44 (first author 6, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
193
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 5 papers · 2020: 6 papers · 2021: 4 papers · 2022: 2 papers · 2023: 3 papers · 2024: 5 papers · 2025: 7 papers · 2026: 9 papers

Papers 44

  1. A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancre… Co-author DOI 10.1002/cncr.70343↗
  2. Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer". Co-author DOI 10.1002/cncr.70510↗
  3. Corrigendum to "Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer" [… Last author DOI 10.1016/j.redox.2026.104395↗
  4. Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-026-04625-x↗
  5. Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41591-026-04775-y↗
  6. Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2025.08.034↗
  7. A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer. Last author DOI 10.1093/oncolo/oyag232↗
  8. The PancreaSure Multianalyte Blood Test Performs Well at Distinguishing Early-Stage Pancreatic Ductal Adenocarcinoma from High-Risk Controls: A Retrospective S… Co-author DOI 10.3390/jcm15197355↗
  9. Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer. Last author DOI 10.36401/jipo-25-20↗
  10. Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer. Last author DOI 10.1016/j.redox.2025.103895↗
  11. Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41416-025-03167-2↗
  12. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Co-author DOI 10.1093/oncolo/oyae323↗
  13. Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma. Last author DOI 10.1177/17588359251321894↗
  14. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  15. Skin microbiome differences in pancreatic adenocarcinoma, other cancers, and healthy controls: a pilot study. Last author DOI 10.3389/fonc.2025.1495500↗
  16. Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol32110638↗
  17. A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2023.09.050↗
  18. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Co-author DOI 10.1093/oncolo/oyae210↗
  19. Hand therapy interventions for the prevention of chemotherapy-induced peripheral neuropathy of the hands in patients with pancreatic cancer. Last author DOI 10.1093/oncolo/oyae285↗
  20. Choroidal metastasis of pancreatic adenocarcinoma: case report. Last author DOI 10.21037/acr-23-86↗
  21. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Me… Co-author DOI 10.3390/cancers16071323↗
  22. A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. Co-author DOI 10.1038/s41467-023-40798-6↗
  23. A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case repor… First author DOI 10.21037/jgo-22-587↗
  24. Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies. First author DOI 10.3389/fonc.2023.1138759↗
  25. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study. Co-author DOI 10.1053/j.gastro.2022.06.090↗
  26. Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib. Last author DOI 10.3390/biomedicines10112705↗
  27. Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-021-04176-w↗
  28. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Co-author DOI 10.1136/jitc-2020-002068↗
  29. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Tr… Co-author DOI 10.1158/1078-0432.ccr-21-0929↗
  30. Role of 3D Volumetric and Perfusion Imaging for Detecting Early Changes in Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.678617↗
  31. Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot C… First author DOI 10.1001/jamaoncol.2019.3394↗
  32. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Co-author DOI 10.1038/s41591-020-0880-x↗
  33. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Co-author DOI 10.1186/s13073-020-00776-9↗
  34. A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1634/theoncologist.2020-0321↗
  35. A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2020-0440↗
  36. An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocar… First author DOI 10.18632/oncotarget.27586↗
  37. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2019.0684↗
  38. Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.32077↗
  39. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Co-author DOI 10.1038/s41586-019-1130-6↗
  40. Neo-adjuvant therapy for pancreatic cancer: hope for the future. Co-author DOI 10.1080/17474124.2019.1607294↗
  41. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  42. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. First author DOI 10.1002/cncr.31628↗
  43. Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma". Co-author DOI 10.1158/1078-0432.ccr-16-2070↗
  44. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Co-author DOI 10.1586/17474124.2014.925799↗

Closest collaborators

The 25 strongest of 193 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel D. Von Hoff · 24 shared papers, 2014–2026 · strength 3.71
  2. Gayle Jameson · 15 shared papers, 2020–2026 · strength 3.10
  3. Haiyong Han · 10 shared papers, 2020–2026 · strength 1.82
  4. Derek Cridebring · 9 shared papers, 2020–2026 · strength 1.59
  5. Ajay Goel · 6 shared papers, 2021–2026 · strength 1.02
  6. Ronald M. Evans · 6 shared papers, 2019–2026 · strength 0.89
  7. Vincent M. Chung · 5 shared papers, 2021–2026 · strength 0.87
  8. Randall E. Brand · 5 shared papers, 2018–2026 · strength 0.87
  9. Michael T. Barrett · 5 shared papers, 2020–2026 · strength 0.86
  10. Carlos Roberto Becerra · 6 shared papers, 2019–2026 · strength 0.85
  11. Norma Alonzo Palma · 3 shared papers, 2025–2026 · strength 0.73
  12. Lisa A. Ford · 3 shared papers, 2025–2026 · strength 0.73
  13. Thomas Charles King · 3 shared papers, 2025–2026 · strength 0.73
  14. Joshua D. Rabinowitz · 3 shared papers, 2025–2026 · strength 0.71
  15. John S. Bolton · 4 shared papers, 2022–2026 · strength 0.70
  16. Eunsung Jun · 4 shared papers, 2022–2026 · strength 0.70
  17. Mitsuro Kanda · 3 shared papers, 2025–2026 · strength 0.61
  18. Song Cheol Kim · 3 shared papers, 2024–2026 · strength 0.59
  19. Joon Oh Park · 4 shared papers, 2020–2026 · strength 0.56
  20. David J. Propper · 3 shared papers, 2023–2026 · strength 0.56
  21. Alexa F. Viniotis · 2 shared papers, 2025–2026 · strength 0.53
  22. Angela Tatiana Alistar · 3 shared papers, 2021–2026 · strength 0.52
  23. Drew Warren Rasco · 2 shared papers, 2026 · strength 0.51
  24. Diana L. Hanna · 2 shared papers, 2026 · strength 0.51
  25. Patricio Marcelo Polanco · 2 shared papers, 2025–2026 · strength 0.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.